Feasibility of Subcutaneous IgPro20 Administration via Manual Push at High Flow Rates in Patients with Primary Immunodeficiency: Findings of the HILO Study

被引：0
|
作者：
Cowan, Juthaporn [1 ]
Bonagura, Vincent [2 ]
Hu, Chengping [3 ]
Lugar, Patricia [4 ]
Maglione, Paul [5 ]
Patel, Niraj [6 ]
Vinh, Donald [7 ]
Hofmann, Jutta [8 ]
Rojavin, Mikhail [8 ]
机构：
[1] Univ Ottawa, Ottawa, ON, Canada
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, East Garden City, NY USA
[3] Allergy Immunol Specialists PLLC, Litchfield Pk, AZ USA
[4] Duke Asthma Allergy & Airway Ctr, Durham, NC USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Levine Childrens Hosp, Charlotte, NC USA
[7] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[8] CSL Behring, King Of Prussia, PA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
699
引用
收藏
页码：AB217 / AB217
页数：1
相关论文
共 27 条
  • [21] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases (vol 6, pg 169, 2013)
    Kanegane, Hirokazu
    Imai, Kohsuke
    Yamada, Masafumi
    Takada, Hidetoshi
    Ariga, Tadashi
    Bexon, Martin
    Rojavin, Mikhail
    Hu, Wilson
    Kobayashi, Midori
    Lawo, John-Philip
    Nonoyama, Shigeaki
    Hara, Toshiro
    Miyawaki, Toshio
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (04) : 520 - 520
  • [22] VALIDATION OF A POPULATION PHARMACOKINETIC MODEL OF SUBCUTANEOUS IMMUNOGLOBULIN (IGPRO20) AFTER WEEKLY AND BIWEEKLY DOSING IN PRIMARY IMMUNODEFICIENCY PATIENTS.
    Zhang, Y.
    Baheti, G.
    Rojavin, M.
    Praus, M.
    Tortorici, M.
    Jochems, J.
    Sidhu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S94 - S94
  • [23] Health-Related Quality Of Life Of Japanese Patients With Primary Immunodeficiency Diseases Receiving IgPro20, a 20% Liquid Subcutaneous Immunoglobulin (Hizentra®)
    Kanegane, Hirokazu
    Imai, Kohsuke
    Yamada, Masafumi
    Takada, Hidetoshi
    Ariga, Tadashi
    Igarashi, Ataru
    Tsutani, Kiichiro
    Bexon, Martin
    Rojavin, Mikhail
    Kobayashi, Midori
    Lawo, John-Philip
    Zbrozek, Art
    Nonoyama, Shigeaki
    Hara, Toshiro
    Miyawaki, Toshio
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB180 - AB180
  • [24] Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push
    Shapiro, R.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 173 (02): : 365 - 371
  • [25] High-flow 20% subcutaneous immunoglobulin G in patients with primary immunodeficiency disease
    McCrary, Kaley
    Leiding, Jennifer W.
    Duff, Carla
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (03) : 344 - 346
  • [26] FEASIBILITY, CLINICAL AND LABORATORY EFFICACY OF LOWER VOLUMES OF SUBCUTANEOUS IMMUNOGLOBULIN ADMINISTRATION VIA MANUAL PUSH TECHNIQUE IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY PATIENTS
    Cocito, D.
    Peci, E.
    Canavese, C.
    Rigaldo, S.
    Falcone, Y.
    Cossa, F.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2019, 24 : S14 - S14
  • [27] Tolerability and onboarding experience with subcutaneous human immune globulin 20% (Ig20Gly) infused at high rates and volumes in pediatric patients with primary immunodeficiency
    Paris, Kenneth
    Hussain, Iftikhar
    Gupta, Sudhir
    Wang, Ping
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 357 - 357
123